ArticleScientific reports2018
Development of local strontium ranelate delivery systems and long term in vitro drug release studies in osteogenic medium.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- MMP-2 Responsive Functional Bladder Acellular Matrix Scaffold Combined With Urine Derived Stem Cells for Bladder Nerve Regeneration.Chembiochem : a European journal of chemical biology · 2026Article
- Toxicological and Cytogenetic Screening of Strontium Ranelate Alone and in Combination With Resveratrol.Chemistry & biodiversity · 2026Article
- From hard tissues to beyond: Progress and challenges of strontium-containing biomaterials in regenerative medicine applications.Bioactive materials · 2025Review
- Strategic incorporation of metal ions in bone regenerative scaffolds: multifunctional platforms for advancing osteogenesis.Regenerative biomaterials · 2025Review
- Apatite/Chitosan Composites Formed by Cold Sintering for Drug Delivery and Bone Tissue Engineering Applications.Nanomaterials (Basel, Switzerland) · 2024Article
- A Comparative Study on Physicochemical Properties andACS applied bio materials · 2023Article
- Strontium Functionalization of Biomaterials for Bone Tissue Engineering Purposes: A Biological Point of View.Materials (Basel, Switzerland) · 2022Review
- Calcium Phosphate/Hyaluronic Acid Composite Hydrogels for Local Antiosteoporotic Drug Delivery.Frontiers in bioengineering and biotechnology · 2022Article
- Incorporation of Barium Ions into Biomaterials: Dangerous Liaison or Potential Revolution?Materials (Basel, Switzerland) · 2021Review
- The Influence of Strontium on Bone Tissue Metabolism and Its Application in Osteoporosis Treatment.International journal of molecular sciences · 2021Review
- Controlled SrR Delivery by the Incorporation of Mg Particles on Biodegradable PLA-Based Composites.Polymers · 2021Article
- Advances in Osteoporotic Bone Tissue Engineering.Journal of clinical medicine · 2021Review
- Automatic Dissolution Testing with High-Temporal Resolution for Both Immediate-Release and Fixed-Combination Drug Tablets.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been recognized that the operative stabilization of osteoporotic fractures should be followed up with an appropriate osteoporosis treatment in order to decrease the risk of repeated fractures. Despite the good clinical results of strontium ranelate (SrRan) towards the osteoporosis treatment, high drug doses and long treatment period cause an increased risk of serious side effects. Novel local SrRan/poly(lactic acid) (SrRan/PLA) delivery systems containing from 3.57 ± 0.28 wt% to 24.39 ± 0.91 wt% of active substance were developed. In order to resemble the naturally occurring processes, osteogenic media (OM) was used as a release medium for long term (121 days) in vitro drug release studies and UV/VIS method for the determination of SrRan content in OM was developed and validated. Biomimetic calcium phosphate precipitates were found on the surface and in the pores of prepared delivery system after microcapsule exposure to OM for 121 days as well as SrRan particles, indicating that the release of the drug have not been completed within 121 days. In vitro cell viability evaluation approved no cytotoxic effects of microcapsule suspensions and extracts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.